caa a22 4500 465789285 CHVBK 20180323112018.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216929 doi (NATIONALLICENCE)springer-10.1007/BF00216929 Phase II evaluation of esorubicin (4′ deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study [Elektronische Daten] [Clarence Vaughn, Sydney Salmon, Thomas Fleming] Summary: Esorubicin (4′ deoxydoxorubicin) is a new analogue of the anthracycline, doxorubicin. This compound lacks the hydroxyl group at 4′ position on the amino sugar of the anthracycline. Phase II study was designed to determine the clinical response rate and to define the qualitative and quantitative toxicities of esorubicin in patients with adenocarcinoma of the pancreas. Fifty-eight patients with inoperable adenocarcinoma of the pancreas were entered on the study, 47 were evaluable for response, and 57 were evaluable for toxicity. The dose of esorubicin was 30 mg/m2 for good risk patients and 25 mg/m2 for poor risk patients every 21 days and administered IV push through a side arm of a running IV. Diphenhydramine, 50 mg is administered IM prior to the administration of the drug to block local venous reaction. Subsequent doses of esorubicin were modified according to granulocyte and platelet nadirs and the drug was not administered until recovery of platelets (> 100,000/ul) and wbc (> 3000/ul). Three partial responses, 20 stable, and 31 with increased disease were observed. Forty-seven had severe granulocytopenia (< 250), and two patients had severe thrombocytopenia (< 25,000). One patient experienced a decrease in left ventricular ejection fraction with a total dose of 180 mg/m2. The dose of esorubicin in this study demonstrated that the drug has minimal activity in adenocarcinoma of the pancreas but the toxicity is tolerable. Search should continue for single agents with activity in this disease. Kluwer Academic Publishers, 1990 esorubicin nationallicence adenocarcinoma/pancreas nationallicence Vaughn Clarence Providence Hospital, Southfield, MI, USA aut Salmon Sydney University of Arizona, Tucson, AZ, USA aut Fleming Thomas Southwest Oncology Group Statistical Center, Seattle, WA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 81-85 0167-6997 8:1<81 1990 8 10637 https://doi.org/10.1007/BF00216929 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216929 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vaughn Clarence Providence Hospital, Southfield, MI, USA aut NATIONALLICENCE 700 1- Salmon Sydney University of Arizona, Tucson, AZ, USA aut NATIONALLICENCE 700 1- Fleming Thomas Southwest Oncology Group Statistical Center, Seattle, WA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 81-85 0167-6997 8:1<81 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer